NCT01274533View on ClinicalTrials.gov

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

May 31, 2013

Conditions

Adult T Cell Leukemia/Lymphoma

Interventions

DRUG

Lenalidomide

25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Columbia University

OTHER

NCT01274533 - Lenalidomide in HTLV-1 Adult T-Cell Leukemia | Biotech Hunter | Biotech Hunter